{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:49:45Z","timestamp":1789670985200,"version":"4.0.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007824","name":"Soochow University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2021.100311","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T17:42:27Z","timestamp":1610646147000},"page":"100311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Lung cancer molecular mutations and abnormal glycosylation as biomarkers for early diagnosis"],"prefix":"10.1016","volume":"27","author":[{"given":"Shuang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeren","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2021.100311_bib0001","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2021.100311_bib0002","unstructured":"Institute NC. 2020 April 15. SEER Cancer Statistics Review (CSR) 1975\u20132017. NCI Surveillance, Epidemiology, and End Results Program <https:\/\/seer.cancer.gov\/csr\/1975_2017\/>. Accessed 2020 April 15."},{"key":"10.1016\/j.ctarc.2021.100311_bib0003","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening","volume":"365","author":"Aberle","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2021.100311_bib0004","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.170070","article-title":"Progress and prospects of early detection in lung cancer","volume":"7","author":"Blandin Knight","year":"2017","journal-title":"Open Biol."},{"key":"10.1016\/j.ctarc.2021.100311_bib0005","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1101\/gr.124347.111","article-title":"Translational genomics: the challenge of developing cancer biomarkers","volume":"22","author":"Brooks","year":"2012","journal-title":"Genome. Res."},{"key":"10.1016\/j.ctarc.2021.100311_bib0006","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.3564","article-title":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","volume":"48","author":"Campbell","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ctarc.2021.100311_bib0007","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/S0140-6736(15)01125-3","article-title":"Large-scale screening for somatic mutations in lung cancer","volume":"387","author":"Rosell","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2021.100311_bib0008","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1056\/NEJMra072367","article-title":"Oncogenes and cancer","volume":"358","author":"Croce","year":"2008","journal-title":"N Eng. J. Med."},{"key":"10.1016\/j.ctarc.2021.100311_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2019.00953","article-title":"New horizons in KRAS-mutant lung cancer: dawn after darkness","volume":"9","author":"Yang","year":"2019","journal-title":"Front Oncol."},{"key":"10.1016\/j.ctarc.2021.100311_bib0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ctarc.2021.100311_bib0011","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1126\/science.1062023","article-title":"The guanine nucleotide-binding switch in three dimensions","volume":"294","author":"Vetter","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ctarc.2021.100311_bib0012","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.csbj.2019.12.004","article-title":"The current understanding of KRAS protein structure and dynamics","volume":"18","author":"Pantsar","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.ctarc.2021.100311_bib0013","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1021\/acs.biochem.7b00974","article-title":"KRAS switch mutants D33E and A59G crystallize in the state 1 conformation","volume":"57","author":"Lu","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.ctarc.2021.100311_bib0014","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-16-0160","article-title":"Systematic functional interrogation of rare cancer variants identifies oncogenic alleles","volume":"6","author":"Kim","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ctarc.2021.100311_bib0015","doi-asserted-by":"crossref","first-page":"e55793","DOI":"10.1371\/journal.pone.0055793","article-title":"Computational analysis of KRAS mutations: implications for different effects on the KRAS p. G12D and p. G13D mutations","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctarc.2021.100311_bib0016","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/568938","article-title":"Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges","volume":"2010","author":"Siwak","year":"2010","journal-title":"J. Oncol."},{"key":"10.1016\/j.ctarc.2021.100311_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms8999","article-title":"Quantitative analysis reveals how EGFR activation and downregulation are coupled in normal but not in cancer cells","volume":"6","author":"Capuani","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2021.100311_bib0018","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2353\/jmoldx.2008.070178","article-title":"EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression","volume":"10","author":"Li","year":"2008","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.ctarc.2021.100311_bib0019","doi-asserted-by":"crossref","first-page":"13574","DOI":"10.1038\/srep13574","article-title":"EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway","volume":"5","author":"Tsai","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2021.100311_bib0020","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1158\/1078-0432.CCR-15-2377","article-title":"Clinical and molecular characteristics of NF1-mutant lung cancer","volume":"22","author":"Redig","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2021.100311_bib0021","doi-asserted-by":"crossref","first-page":"22122","DOI":"10.1073\/pnas.1908353116","article-title":"KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis","volume":"116","author":"Rabara","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ctarc.2021.100311_bib0022","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1158\/0008-5472.CAN-13-0681","article-title":"Mutationally activated PIK3CAH1047R cooperates with BRAFV600E to promote lung cancer progression","volume":"73","author":"Trejo","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2021.100311_bib0023","doi-asserted-by":"crossref","first-page":"22976","DOI":"10.3390\/ijms160922976","article-title":"Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers","volume":"16","author":"Temraz","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2021.100311_bib0024","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1021\/bi500182x","article-title":"Recruitment of the adaptor protein Grb2 to EGFR tetramers","volume":"53","author":"Kozer","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.ctarc.2021.100311_bib0025","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1158\/1078-0432.CCR-05-1554","article-title":"The epidermal growth factor receptor pathway: a model for targeted therapy","volume":"12","author":"Scaltriti","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2021.100311_bib0026","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.trecan.2017.08.006","article-title":"KRAS alleles: the devil is in the detail","volume":"3","author":"Haigis","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ctarc.2021.100311_bib0027","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2021.100311_bib0028","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1126\/science.aad6204","article-title":"Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism","volume":"351","author":"Lito","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ctarc.2021.100311_bib0029","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nm1208-1315","article-title":"Targeting RAS and PI3K in lung cancer","volume":"14","author":"Downward","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.ctarc.2021.100311_bib0030","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/aps.2014.129","article-title":"The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer","volume":"36","author":"Guin","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.ctarc.2021.100311_bib0031","series-title":"Am. Soc. Clin. Oncol.","article-title":"A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors","author":"Gort","year":"2020"},{"key":"10.1016\/j.ctarc.2021.100311_bib0032","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/onc.2009.198","article-title":"Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors","volume":"28","author":"Gazdar","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.ctarc.2021.100311_bib0033","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1073\/pnas.1313733111","article-title":"Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance","volume":"111","author":"Schwartz","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ctarc.2021.100311_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115018","article-title":"The selective c-Met inhibitor capmatinib offsets cisplatin-nephrotoxicity and doxorubicin-cardiotoxicity and improves their anticancer efficacies","volume":"398","author":"Shaker","year":"2020","journal-title":"Toxicol. Appl. Pharmaco."},{"key":"10.1016\/j.ctarc.2021.100311_bib0035","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-10-2214","article-title":"Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells","volume":"17","author":"Diep","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2021.100311_bib0036","doi-asserted-by":"crossref","first-page":"D261","DOI":"10.1093\/nar\/gkr1122","article-title":"PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse","volume":"40","author":"Hornbeck","year":"2012","journal-title":"Nucleic. Acids. Res."},{"key":"10.1016\/j.ctarc.2021.100311_bib0037","doi-asserted-by":"crossref","first-page":"e40674","DOI":"10.1371\/journal.pone.0040674","article-title":"L1CAM binds ErbB receptors through Ig-like domains coupling cell adhesion and neuregulin signalling","volume":"7","author":"Donier","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctarc.2021.100311_bib0038","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrc.2017.5","article-title":"Tissue-specific tumorigenesis: context matters","volume":"17","author":"Schneider","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ctarc.2021.100311_bib0039","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/brain\/awy307","article-title":"High prevalence of KRAS\/BRAF somatic mutations in brain and spinal cord arteriovenous malformations","volume":"142","author":"Hong","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.ctarc.2021.100311_bib0040","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/s41388-018-0575-7","article-title":"Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis","volume":"38","author":"Weng","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.ctarc.2021.100311_bib0041","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/annonc\/mdq680","article-title":"Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer","volume":"22","author":"Garassino","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2021.100311_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-018-0719-1","article-title":"Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities","volume":"37","author":"Porru","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2021.100311_bib0043","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1479-5876-12-147","article-title":"Detection of activated KRAS from cancer patient peripheral blood using a weighted enzymatic chip array","volume":"12","author":"Huang","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ctarc.2021.100311_bib0044","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1158\/1078-0432.CCR-09-2672","article-title":"Potential clinical significance of a plasma-based kras mutation analysis in patients with advanced non\u2013small cell lung cancer","volume":"16","author":"Wang","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2021.100311_bib0045","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early-and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ctarc.2021.100311_bib0046","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1634\/theoncologist.2016-0458","article-title":"Targeting BRAF-mutant non-small cell lung cancer: from molecular profiling to rationally designed therapy","volume":"22","author":"Baik","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2021.100311_bib0047","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.21037\/jtd.2018.12.18","article-title":"Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives","volume":"11","author":"Herbreteau","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.ctarc.2021.100311_bib0048","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I","article-title":"Regulation of the cdk inhibitor p27 and its deregulation in cancer","volume":"183","author":"Slingerland","year":"2000","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.ctarc.2021.100311_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.120941","article-title":"Requirement for MUC5AC in KRAS-dependent lung carcinogenesis","volume":"3","author":"Bauer","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ctarc.2021.100311_bib0050","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10719-016-9755-2","article-title":"Glycosylation: a hallmark of cancer?","volume":"34","author":"Vajaria","year":"2017","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.ctarc.2021.100311_bib0051","doi-asserted-by":"crossref","first-page":"10231","DOI":"10.1073\/pnas.172380699","article-title":"Glycosylation defining cancer malignancy: new wine in an old bottle","volume":"99","author":"Hakomori","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ctarc.2021.100311_bib0052","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc3982","article-title":"Glycosylation in cancer: mechanisms and clinical implications","volume":"15","author":"Pinho","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ctarc.2021.100311_bib0053","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/CBM-130375","article-title":"The Cosmc connection to the Tn antigen in cancer","volume":"14","author":"Ju","year":"2014","journal-title":"Cancer Biomark"},{"key":"10.1016\/j.ctarc.2021.100311_bib0054","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cellimm.2018.03.007","article-title":"Glycosylation in cancer: selected roles in tumour progression, immune modulation and metastasis","volume":"333","author":"Rodrigues","year":"2018","journal-title":"Cell Immunol."},{"key":"10.1016\/j.ctarc.2021.100311_bib0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12014-017-9166-9","article-title":"Protein signatures of molecular pathways in non-small cell lung carcinoma (NSCLC): comparison of glycoproteomics and global proteomics","volume":"14","author":"Yang","year":"2017","journal-title":"Clin. Proteomics."},{"key":"10.1016\/j.ctarc.2021.100311_bib0056","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1158\/0008-5472.CAN-07-6389","article-title":"Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells","volume":"68","author":"Contessa","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2021.100311_bib0057","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1515\/CCLM.2002.047","article-title":"Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA)","volume":"40","author":"Giovanella","year":"2002","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.ctarc.2021.100311_bib0058","first-page":"581","article-title":"Cut-off levels of NSE to differentiate SCLC from NSCLC","volume":"9","author":"Satoh","year":"2002","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ctarc.2021.100311_bib0059","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12967-019-1828-0","article-title":"The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients","volume":"17","author":"Dal Bello","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ctarc.2021.100311_bib0060","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1158\/1078-0432.CCR-13-0046","article-title":"Isocitrate Dehydrogenase 1 Is a novel plasma biomarker for the diagnosis of non\u2013small cell lung cancer","volume":"19","author":"Sun","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2021.100311_bib0061","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/ajco.12066","article-title":"Evaluation of diagnostic value of four tumor markers in bronchoalveolar lavage fluid of peripheral lung cancer","volume":"10","author":"Li","year":"2014","journal-title":"Asia Pac. J. Clin. Nutr."},{"key":"10.1016\/j.ctarc.2021.100311_bib0062","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1021\/ac400761e","article-title":"Glycomic analysis using glycoprotein immobilization for glycan extraction","volume":"85","author":"Yang","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ctarc.2021.100311_bib0063","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/nprot.2017.034","article-title":"Simultaneous quantification of N-and O-glycans using a solid-phase method","volume":"12","author":"Yang","year":"2017","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ctarc.2021.100311_bib0064","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12014-017-9137-1","article-title":"Simultaneous analyses of N-linked and O-linked glycans of ovarian cancer cells using solid-phase chemoenzymatic method","volume":"14","author":"Yang","year":"2017","journal-title":"Clin. Proteomics"},{"key":"10.1016\/j.ctarc.2021.100311_bib0065","doi-asserted-by":"crossref","first-page":"8261","DOI":"10.1021\/acs.analchem.8b01834","article-title":"Deciphering protein O-glycosylation: solid-phase chemoenzymatic cleavage and enrichment","volume":"90","author":"Yang","year":"2018","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ctarc.2021.100311_bib0066","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221000101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221000101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:22:28Z","timestamp":1762842148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294221000101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":66,"alternative-id":["S2468294221000101"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100311","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lung cancer molecular mutations and abnormal glycosylation as biomarkers for early diagnosis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100311"}}